Endothelial LRP1 transports amyloid-β1-42 across the blood-brain barrier

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 123-136

  Storck, Steffen E ^a   Meister, Sabrina ^a   Nahrath, Julius ^a   Meißner, Julius N ^b   Schubert, Nils ^b   Di Spiezio, Alessandro ^c   Baches, Sandra ^d   Vandenbroucke, Roosmarijn E ^e,f   Bouter, Yvonne ^b   Prikulis, Ingrid ^d   Korth, Carsten ^d   Weggen, Sascha ^d   Heimann, Axel ^a   Schwaninger, Markus ^c   Bayer, Thomas A ^b   Pietrzik, Claus U ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CD11B ANTIGEN; CRE RECOMBINASE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; TAMOXIFEN; AMYLOID BETA-PROTEIN (1-42); LOW DENSITY LIPOPROTEIN RECEPTOR; LRP1 PROTEIN, MOUSE; PEPTIDE FRAGMENT; TUMOR SUPPRESSOR PROTEIN;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CHOROID PLEXUS; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE DELETION; GENE MUTATION; GLIA CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LEARNING DISORDER; MACROPHAGE; MICROGLIA; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REFERENCE MEMORY; SPATIAL LEARNING; TRANSCYTOSIS; ANIMAL; BRAIN; C57BL MOUSE; COGNITION DISORDERS; METABOLISM; PHYSIOLOGY;

AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; COGNITION DISORDERS; ENDOTHELIAL CELLS; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PROTEIN TRANSPORT; RECEPTORS, LDL; TRANSCYTOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84956617728     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81108     Document Type: Article

References (66)

1. Mawuenyega KG, et al. Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science. 2010;330(6012):1774.
2. Naslund J, et al. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A. 1994;91(18):8378-8382.
3. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005;28(4):202-208.
4. Tarasoff-Conway JM, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457-470.
5. Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-β peptide in a blood-brain barrier in vitro model. Neurobiol Dis. 2008;30(1):94-102.
6. Kanekiyo T, et al. Neuronal clearance of amyloid-β by endocytic receptor LRP1. J Neurosci. 2013;33(49):19276-19283.
7. Kanekiyo T, Liu CC, Shinohara M, Li J, Bu G. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. J Neurosci. 2012;32(46):16458-16465.
8. Shibata M, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106(12):1489-1499.
9. Silverberg GD, et al. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol. 2010;69(10):1034-1043.
10. Kang DE, et al. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest. 2000;106(9):1159-1166.
11. Bell RD, et al. Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27(5):909-918.
12. Deane R, et al. apoE Isoform-specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest. 2008;118(12):4002-4013.
13. Zhao Z, et al. Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci. 2015;18(7):978-987.
14. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the α2-macroglobulin receptor/ low-density-lipoprotein receptor-related protein. Ann Neurol. 1995;37(2):211-217.
15. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004;35(11 suppl 1):2628-2631.
16. Roberts KF, et al. Amyloid-β efflux from the CNS into the plasma. Ann Neurol. 2014;76(6):837-844.
17. Ito S, Ueno T, Ohtsuki S, Terasaki T. Lack of brainto-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-β peptide(1-40) in mouse: involvement of an LRP-1-independent pathway. J Neurochem. 2010;113(5):1356-1363.
18. Ito S, Ohtsuki S, Kamiie J, Nezu Y, Terasaki T. Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J Neurochem. 2007;103(6):2482-2490.
19. Yamada K, et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid β peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem. 2008;283(50):34554-34562.
20. Candela P, et al. In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes. Brain Res. 2015;1594:15-26.
21. Qosa H, et al. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology. 2014;79:668-678.
22. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1992;71(3):411-421.
23. Herz J, Couthier DE, Hammer RE. Correction: LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1993;73(3):428.
24. Ridder DA, et al. TAK1 in brain endothelial cells mediates fever and lethargy. J Exp Med. 2011;208(13):2615-2623.
25. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998;101(3):689-695.
26. Leneuve P, Zaoui R, Monget P, Le Bouc Y, Holzenberger M. Genotyping of Cre-lox mice and detection of tissue-specific recombination by multiplex PCR. Biotechniques. 2001;31(5):1156-1160.
27. Bu G, Maksymovitch EA, Nerbonne JM, Schwartz AL. Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J Biol Chem. 1994;269(28):18521-18528.
28. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88(3):887-918.
29. Wolf BB, Lopes MB, VandenBerg SR, Gonias SL. Characterization and immunohistochemical localization of α2-macroglobulin receptor (low-density lipoprotein receptorrelated protein) in human brain. Am J Pathol. 1992;141(1):37-42.
30. Tooyama I, et al. Subcellular localization of the low density lipoprotein receptor-related protein (α2-macroglobulin receptor) in human brain. Brain Res. 1995;691(1-2):235-238.
31. Tooyama I, Kawamata T, Akiyama H, Moestrup SK, Gliemann J, McGeer PL. Immunohistochemical study of α2 macroglobulin receptor in Alzheimer and control postmortem human brain. Mol Chem Neuropathol. 1993;18(1-2):153-160.
32. Pflanzner T, et al. LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier. Neurobiol Aging. 2011;32(12):2323 e1-2323 11.
33. Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis. 2012;31(1):151-165.
34. Pflanzner T, et al. Cellular prion protein participates in amyloid-β transcytosis across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(4):628-632.
35. Li Y, Lu W, Marzolo MP, Bu G. Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J Biol Chem. 2001;276(21):18000-18006.
36. Davis J, et al. Early-onset and robust cerebral microvascular accumulation of amyloid β-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid β-protein precursor. J Biol Chem. 2004;279(19):20296-20306.
37. Oakley H, et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129-10140.
38. Wyss-Coray T, et al. TGF-β1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7(5):612-618.
39. Wyss-Coray T, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med. 2003;9(4):453-457.
40. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11(1):47-60.
41. Bouter Y, et al. N-truncated amyloid beta (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol. 2013;126(2):189-205.
42. Heyser CJ. Assessment of developmental milestones in rodents. Curr Protoc Neurosci. 2004;Chapter 8:Unit 8.18.
43. Bouter Y, et al. Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing. Front Aging Neurosci. 2014;6:75.
44. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 2002;33(4):1152-1162.
45. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5(5):347-360.
46. Pi X, et al. LRP1-dependent endocytic mechanism governs the signaling output of the bmp system in endothelial cells and in angiogenesis. Circ Res. 2012;111(5):564-574.
47. Pflanzner T, Kuhlmann CR, Pietrzik CU. Bloodbrain-barrier models for the investigation of transporter-and receptor-mediated amyloid-β clearance in Alzheimer's disease. Curr Alzheimer Res. 2010;7(7):578-590.
48. Wang X, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9(10):1313-1317.
49. Kanekiyo T, Bu G. The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer's disease. Front Aging Neurosci. 2014;6:93.
50. Deane R, et al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron. 2004;43(3):333-344.
51. Sagare A, et al. Clearance of amyloid-β by circulating lipoprotein receptors. Nat Med. 2007;13(9):1029-1031.
52. Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1-40) across the rat blood-brain barrier. Neurosci Res. 2006;56(3):246-252.
53. Tuma P, Hubbard AL. Transcytosis: crossing cellular barriers. Physiol Rev. 2003;83(3):871-932.
54. Dodart JC, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci. 2002;5(5):452-457.
55. McLean CA, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46(6):860-866.
56. Mc Donald JM, et al. The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia. Brain. 2010;133(pt 5):1328-1341.
57. Ulery PG, et al. Modulation of β-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem. 2000;275(10):7410-7415.
58. van Beijnum JR, Rousch M, Castermans K, van der Linden E, Griffioen AW. Isolation of endothelial cells from fresh tissues. Nat Protoc. 2008;3(6):1085-1091.
59. Deane R, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012;122(4):1377-1392.
60. Deane R, Zheng W, Zlokovic BV. Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. J Neurochem. 2004;88(4):813-820.
61. Cirrito JR, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115(11):3285-3290.
62. Vandenbroucke RE, et al. Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. J Neurosci. 2012;32(29):9805-9816.
63. Hahn S, et al. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure. J Neurochem. 2011;116(3):385-395.
64. Wirths O, et al. Pyroglutamate Aβ pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm. 2010;117(1):85-96.
65. Wittnam JL, et al. Pyroglutamate amyloid beta (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J Biol Chem. 2012;287(11):8154-8162.
66. Korth C, Streit P, Oesch B. Monoclonal antibodies specific for the native, disease-associated isoform of the prion protein. Methods Enzymol. 1999;309:106-122.